Genentech’s Lucentis® (ranibizumab injection) 0.3 mg is now approved for the monthly treatment of all forms of diabetic retinopathy. Diabetic retinopathy is the most common cause of vision loss in people with diabetes and the leading cause of blindness among adults aged 20 to 74.  Lucentis is the first and only medicine FDA-approved to treat all forms of diabetic retinopathy.